Setback To Novartis: CDSCO Panel Rejects Lanalumab Phase III Trial Design Over Study Flaws
New Delhi: In a setback to Novartis, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has declined to approve the current design of the Phase III clinical trial protocol for its monoclonal antibody Lanalumab (VAY736), citing concerns over the study rationale and treatment strategy.
The firm had submitted Protocol No. CVAY736K12301E1 Version 00 dated 14 August 2024 for the committee’s consideration.
Lanalumab, also known as VAY736, is a monoclonal antibody targeting the BAFF receptor (BAFF-R). It is being investigated for autoimmune diseases such as Sjögren's syndrome, systemic lupus erythematosus (SLE), and multiple sclerosis.
At the SEC (Renal) meeting held on July 22, 2025, the expert panel deliberated on the protocol and concluded that the proposed study design could not be approved in its current format due to the following concerns:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.